Who are Intravitreal Methotrexate 400 µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Methotrexate (stable dose), Methotrexate (tapering dose), Methotrexate tablets, Methotrexate therapy, Methotrexate Monotherapy, MTX.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravitreal-methotrexate-400-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Intravitreal Methotrexate 400 µg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravitreal Methotrexate 400 µg (Intravitreal Methotrexate 400 µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite; Folate antagonist. Area: Oncology.

phase 3 Antimetabolite; Folate antagonist Dihydrofolate reductase (DHFR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Intravitreal Methotrexate 400 µg (Intravitreal Methotrexate 400 µg) — JHSPH Center for Clinical Trials. Intravitreal methotrexate is a chemotherapy agent injected directly into the eye that inhibits dihydrofolate reductase, suppressing DNA synthesis and reducing proliferation of malignant cells in ocular lymphomas.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intravitreal Methotrexate 400 µg TARGET	Intravitreal Methotrexate 400 µg	JHSPH Center for Clinical Trials	phase 3	Antimetabolite; Folate antagonist	Dihydrofolate reductase (DHFR)
Methotrexate (stable dose)	Methotrexate (stable dose)	Hoffmann-La Roche	marketed	Antimetabolite; Folate antagonist	Dihydrofolate reductase (DHFR)
Methotrexate (tapering dose)	Methotrexate (tapering dose)	Hoffmann-La Roche	marketed	Antimetabolite / Folate antagonist	Dihydrofolate reductase (DHFR)
Methotrexate tablets	Methotrexate tablets	Yancheng First People's Hospital	marketed	Antimetabolite / Folate antagonist	Dihydrofolate reductase (DHFR)
Methotrexate therapy	Methotrexate therapy	National Medical Research Center for Children's Health, Russian Federation	marketed	Folate antagonist / Antimetabolite	Dihydrofolate reductase (DHFR)
Methotrexate Monotherapy	Methotrexate Monotherapy	Bangladesh Medical University	marketed	Antimetabolite / Folate antagonist	Dihydrofolate reductase (DHFR)
MTX	MTX	South China Children's Leukemia Group	marketed	Antimetabolite; folate antagonist	Dihydrofolate reductase (DHFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite; Folate antagonist class)

Centocor, Inc. · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
JHSPH Center for Clinical Trials · 1 drug in this class
University Hospital, Bordeaux · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravitreal Methotrexate 400 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/intravitreal-methotrexate-400-g. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab